The pivotal role of microRNA in diagnosing and monitoring cancer is well known by today’s researchers. “There have been a lot of studies in recent years linking the presence and concentration of specific microRNA sequences to clinical outcomes for people with advanced prostate cancer,” said Brian Cunningham (CGD leader/MMG), a professor of electrical and computer engineering and a program leader at the Cancer Center at Illinois.

Despite recent years’ dramatic improvements in cancer treatment, cancer remains second only to heart disease as a leading cause of death for Americans. But a new Nature Communications paper has reported exactly the kind of breakthrough that cancer patients yearn for: development of a highly sensitive new method for performing a liquid biopsy that can identify tiny numbers of individual cancer molecules.

MNTL & IGB Team Up to Develop Use-at-Home Sample Collection Assay for Cancer Patients

Courtesy of Micro & Nanotechnology Laboratory.